v3.26.1
Stockholders' Equity (Tables)
6 Months Ended
Jun. 30, 2026
Equity [Abstract]  
Summary of Warrants and Pre-funded Warrants to Purchase Shares of Common Stock Issued and Outstanding

The following warrants and pre-funded warrants to purchase shares of the Company's common stock were issued and outstanding:

Issue Date

 

Exercisable Date

 

Expiration Date

 

Exercise Price per Share

 

 

June 30,
2026

 

 

December 31,
2025

 

6/16/2024

 

6/16/2024

 

6/18/2029

 

$

17.00

 

 

 

634,500

 

 

 

634,500

 

6/17/2024

 

6/17/2024

 

6/18/2029

 

$

17.00

 

 

 

179,500

 

 

 

179,500

 

8/11/2025

 

8/11/2025

 

No expiration

 

$

0.001

 

 

 

1,040,820

 

 

 

1,040,820

 

8/11/2025

 

8/11/2025

 

8/11/2030 (1)

 

$

21.60

 

 

 

4,209,187

 

 

 

4,209,187

 

8/11/2025

 

11/15/2026 (2)

 

12/31/2026 (2)

 

$

21.60

 

 

 

4,464,290

 

 

 

4,464,290

 

5/26/2026

 

5/26/2026

 

No expiration

 

$

0.001

 

 

 

415,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10,943,297

 

 

 

10,528,297

 

(1)
These Class A warrants will expire 30 days following the public announcement that the Company completed enrollment (of at least 200 patients total) in the Phase 2 clinical study evaluating 5366 versus valacyclovir if prior to August 11, 2030.
(2)
These Class B warrants will be cancelled if the Company publicly announces the receipt of at least $75.0 million in the aggregate of non-dilutive capital in connection with a collaboration agreement prior to November 15, 2026.